Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. (RVMD)
Company Research
Source: GlobeNewswire
Encouraging progression-free survival and overall survival profile Safety findings consistent with previously reported data, no new safety signals observed Investor webcast to be held Friday, October 25 at 12:00 p.m. Eastern Time (ET) REDWOOD CITY, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced encouraging antitumor activity and safety/tolerability data for RMC-6236, its RAS(ON) multi-selective inhibitor, in patients with previously treated pancreatic ductal adenocarcinoma (PDAC). These updated results were presented during a late-breaking poster session at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, October 23-25, 2024. “The maturing data reported today continue to solidify the compelling progression-free survival and overall survival for patients with pancreatic cancer treated with RMC-6236,
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at HC Wainwright from $62.00 to $64.00. They now have a "buy" rating on the stock.MarketBeat
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Needham & Company LLC from $61.00 to $68.00. They now have a "buy" rating on the stock.MarketBeat
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at JPMorgan Chase & Co. from $54.00 to $63.00. They now have an "overweight" rating on the stock.MarketBeat
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Piper Sandler from $57.00 to $70.00. They now have an "overweight" rating on the stock.MarketBeat
RVMD
Earnings
- 11/6/24 - Miss
RVMD
Sec Filings
- 11/19/24 - Form 4
- 11/15/24 - Form 144
- 11/15/24 - Form 4
- RVMD's page on the SEC website